A carregar...
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Schizophrenia affects approximately 1% of the population and continues to be associated with poor outcome because of the limited efficacy of and noncompliance with existing antipsychotic medications. An alternative hypothesis invoking the excitatory neurotransmitter, glutamate, arose out of clinical...
Na minha lista:
| Publicado no: | Handb Exp Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4817347/ https://ncbi.nlm.nih.gov/pubmed/23027419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/978-3-642-25758-2_10 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|